Cibinqo (abrocitinib) Prior Authorization for Atopic Dermatitis
Customize your policy alerts
Sign up for all Colorado Rocky Mountain Health Plans policy alerts
Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Cibinqo tablets used to treat moderate-to-severe atopic dermatitis in adults and patients age 12 years and older. It defines initial authorization, continuation, documentation, prescriber, treatment-history, and combination-therapy requirements.
The policy was reviewed with no change to the critical coverage criteria.
The background was updated to reflect the indication for patients 12 years of age and older.
The topical-therapy step requirement was updated to include generic pimecrolimus and tacrolimus.
Topical corticosteroid potency categories were clarified without changing clinical intent or coverage criteria.
Ebglyss was added as an example of a systemic drug product and Nemluvio was added as a try-and-fail option.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.